Digital PCR Improves Sensitivity and Quanti fi cation in Monitoring CAR-T Cells in B Cell Lymphoma Patients

被引:4
|
作者
de la Iglesia-San Sebastian, Ismael [1 ,2 ]
Carbonell, Diego [1 ,2 ]
Bastos-Oreiro, Mariana [1 ,2 ]
Perez-Corral, Ana [1 ,2 ]
Bailen, Rebeca [1 ,2 ]
Chicano, Maria [1 ,2 ]
Muniz, Paula [1 ,2 ]
Monsalvo, Silvia [1 ,2 ]
Escudero-Fernandez, Asuncion [1 ]
Oarbeascoa, Gillen [1 ,2 ]
Fernandez-Caldas, Paula [1 ,2 ]
Gomez-Centurion, Ignacio [1 ,2 ]
Pion, Marjorie [3 ]
Gayoso, Jorge [1 ,2 ]
Anguita, Javier [1 ,2 ]
Kwon, Mi [1 ,2 ]
Diez-Martin, Jose Luis [1 ,2 ,4 ]
Buno, Ismael [1 ,2 ,5 ]
Martinez-Laperche, Carolina [1 ,2 ,6 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Dept Hematol, Madrid, Spain
[2] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[3] Inst Invest Sanitaria Gregorio Maranon, Adv Immuno Regulat Grp, Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[4] Univ Complutense Madrid, Dept Med, Madrid, Spain
[5] Genom Unit, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[6] Gregorio Maranon Gen Univ Hosp, Gregorio Maranon Hlth Res Inst IiSGM, Dept Hematol, C Doctor Esquerdo 46, Madrid 28007, Spain
来源
TRANSPLANTATION AND CELLULAR THERAPY | 2024年 / 30卷 / 03期
关键词
CAR-T cells; Digital PCR; Monitoring; Relapse; Sensitivity; Toxicity; THERAPY;
D O I
10.1016/j.jtct.2023.12.672
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chimeric antigen receptor T cells (CAR-T) has emerged as a promising therapy, over 60% of patients fail to sustain a long-term response. The underlying factors that leads to the effectiveness of this therapy are not completely understood, CAR-T cell persistence and monitoring seems to be pivotal for ensuring a successful response. Various monitoring methods such as multiparametric flow cytometry (MFC) or quantitative PCR (qPCR) have been applied. Our objective is to develop digital PCR (dPCR) assays for detection and quanti fication of CAR-T cells, comparing them with MFC and qPCR. Samples taken at different follow-up times from 45 patients treated with CAR-T therapy were analyzed to assess the correlation between the different methodologies. dPCR presented a high correlation with MFC and qPCR (r = 0.97 and r = 0.87, respectively), while offering a higher sensitivity (0.01%) compared to MFC (0.1%) and qPCR (1%). dPCR emerged as an alternative and highly sensitivity method for monitoring CAR-T cell dynamics. This technique is well-suited for implementation in clinical practice as a complementary technique to MFC. (c) 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页码:306e1 / 306e12
页数:12
相关论文
共 50 条
  • [41] Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma
    Bansal, Radhika
    Paludo, Jonas
    Corraes, Andre De Menezes Silva
    Megan, Spychalla
    Khurana, Arushi
    Hampel, Paul Joseph
    Durani, Urshila
    Dingli, David
    Hayman, Suzanne R.
    Kapoor, Prashant
    Wang, Yucai
    Binder, Moritz
    Kourelis, Taxiarchis
    Kumar, Shaji
    Warsame, Rahma M.
    Bennani, Nabila Nora
    Gertz, Morie A.
    Johnston, Patrick B.
    Ansell, Stephen M.
    Lin, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
    Saha, Aditi
    Jhaveri, Khushali
    Sarfraz, Humaira
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, : 869 - 876
  • [43] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
    Saha, Aditi
    Jhaveri, Khushali
    Sarfraz, Humaira
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023,
  • [44] The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
    Albanyan, Omar
    Chavez, Julio
    Munoz, Javier
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [45] Regional Injection of CAR-T Cells for the Treatment of Refractory and Recurrent Diffuse Large B Cell Lymphoma: A Case Report
    Wei, Yan-Hui
    He, Yu-Zhuo
    Lin, Xiao-Yan
    Ren, Fu-Xian
    Zhu, Hong-Bin
    Cheng, Ying
    Nan, Zhen
    Liu, Zheng-Biao
    Yu, Jing-Ya
    Guo, Xue-Jun
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [46] The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
    Albanyan, Omar
    Chavez, Julio
    Munoz, Javier
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [47] Preclinical development of bispecific CAR-T cells for canine B cell malignancies
    Atherton, Matthew J.
    Rotolo, Antonia
    Mason, Nicola J.
    CANCER RESEARCH, 2022, 82 (12)
  • [48] Functional and translatable efficacy of CAR-T cells targeting B cell lymphomas
    Kelsey, Lauren
    Latta, Karin
    Kolb, Joey
    John, Bincy
    Aylott, Ilona
    Rocca, Daniel
    Bacita, Alexandru
    Kirkham, Christopher
    Walters, Patrick
    Humphery, Charlotte
    Ballesteros, Lorena Sueiro
    Self-Fordham, Jezrom
    Brackenbury, Louise
    Hall, Chassidy
    David, Harris
    Schueler, Julia
    Nunan, Robert
    CANCER RESEARCH, 2023, 83 (07)
  • [49] Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma
    Maldonado-Perez, Noelia
    Tristan-Manzano, Maria
    Justicia-Lirio, Pedro
    Martinez-Planes, Elena
    Munoz, Pilar
    Pavlovic, Kristina
    Cortijo-Gutierrez, Marina
    Blanco-Benitez, Carlos
    Castella, Maria
    Juan, Manel
    Wenes, Mathias
    Romero, Pedro
    Molina-Estevez, Francisco J.
    Maranon, Concepcion
    Herrera, Concha
    Benabdellah, Karim
    Martin, Francisco
    FRONTIERS IN IMMUNOLOGY, 2022, 13